DK2046298T3 - Farmaceutisk doseringsform indeholdende farmaceutisk acceptabel solubiliserende sammensætning - Google Patents
Farmaceutisk doseringsform indeholdende farmaceutisk acceptabel solubiliserende sammensætning Download PDFInfo
- Publication number
- DK2046298T3 DK2046298T3 DK07787658.9T DK07787658T DK2046298T3 DK 2046298 T3 DK2046298 T3 DK 2046298T3 DK 07787658 T DK07787658 T DK 07787658T DK 2046298 T3 DK2046298 T3 DK 2046298T3
- Authority
- DK
- Denmark
- Prior art keywords
- dosage form
- weight
- melt
- amino
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (13)
1. Farmaceutisk doseringsform, der omfatter en smelteforarbejdet blanding af mindst én aktiv bestanddel, mindst én farmaceutisk acceptabel homopolymer eller copolymer af N-vinylpyrrolidon og en solubiliserende sammensætning, hvilken aktive bestanddel er til stede som en fast dispersion og hvilken solubiliserende sammensætning omfatter (i) mindst én tocopherylforbindelse, der svarer til formel (i)
hvor Z er resten af en alifatisk dibasisk syre, R1 og R2 er, uafhængigt af hinanden, hydrogen eller Ci-C4-alkyl og n er et helt tal fra 5 til 100, og (ii) mindst en propylenglycolfedtsyremonoester eller blanding af propylengly-colfedtsyremono- og di-estere, hvori doseringsformen omfatter, i forhold til vægten af den smelteforarbejdede blanding, fra ca. 0,5 til 40 vægt-% af den aktive bestanddel, 40 til 99 vægt-% af den farmaceutisk acceptable homopolymer eller copolymer af N-vinylpyrrolidon, 0,5 til 20 vægt-% af den nævnte solubiliserende sammensætning, og fra 0 til 15 vægt-% af additiver.
2 Doseringsformen ifølge krav 1, hvor tocopherylforbindelsen er alfa-tocophe-rylpolyethylenglycolsuccinat.
3. Doseringsformen ifølge krav 1 eller 2, hvor propylenglycolfedtsyremono-esteren er propylenglycolmonolaurat.
4. Doseringsform ifølge ethvert af de foregående krav, hvor vægtforholdet mellem tocopherylforbindelsen og propylenglycolfedtsyreesteren er i området fra 9:1 til 1:9.
5. Doseringsform ifølge ethvert af de foregående krav, hvor den aktive bestanddel er en HIV-proteaseinhibitor eller en kombination af HlV-proteaseinhibi-torer.
6. Doseringsformen ifølge krav 5, hvor HIV-proteaseinhibitoren er valgt fra gruppen bestående af: (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazo-lyl)methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbo-nyl)amino)amino-1,6-diphenyl-3-hydroxyhexan (ritonavir); (2S,3S,5S)-2-(2,6-di-methylphenoxyacetyl)amino-3-hydroxy-5-[2S-(l-tetrahydro-pyrimid-2-onyl)-3-methylbutanoyl]amino-1,6-diphenylhexan (lopinavir); eller kombinationer deraf.
7. Fast doseringsform ifølge ethvert af de foregående krav, hvor den farmaceutisk acceptable homopolymer eller copolymer af N-vinylpyrrolidon er en copolymer af N-vinylpyrrolidon og vinylacetat.
8. Fast doseringsform ifølge ethvert af de foregående krav, der indeholder mindst et additiv valgt fra strømningsregulatorer, sprængmidler, fyldstoffer og smøremidler.
9. Fast doseringsform ifølge ethvert af de foregående krav, hvor den smelteforarbejdede blanding har et Tg på 10 °C eller højere.
10. Fremgangsmåde til fremstilling af en fast doseringsform ifølge krav 1, som omfatter: a) fremstilling af en homogen smelte af den eller de nævnte aktive bestanddele, den eller de farmaceutisk acceptable homopolymere eller copolymere af N-vi-nylpyrrolidon og den nævnte solubiliserende sammensætning, og b) at tillade smelten at størkne til opnåelse af et fast dispersionsprodukt.
11. Fremgangsmåden ifølge krav 10, der yderligere omfatter formaling af det faste dispersionsprodukt og komprimere det faste dispersionsprodukt til en tablet.
12. Fremgangsmåden ifølge krav 10, der yderligere omfatter formaling af det faste dispersionsprodukt og påfyldning af det faste dispersionsprodukt i en kapselskal.
13. Fremgangsmåden ifølge krav 10, hvor smelten formes til en film eller et skum, før den får lov at størkne.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83207406P | 2006-07-19 | 2006-07-19 | |
EP06015076A EP1880715A1 (en) | 2006-07-19 | 2006-07-19 | Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same |
PCT/EP2007/057392 WO2008009689A1 (en) | 2006-07-19 | 2007-07-17 | Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2046298T3 true DK2046298T3 (da) | 2017-03-13 |
Family
ID=37496705
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK07787658.9T DK2046298T3 (da) | 2006-07-19 | 2007-07-17 | Farmaceutisk doseringsform indeholdende farmaceutisk acceptabel solubiliserende sammensætning |
Country Status (22)
Country | Link |
---|---|
US (2) | US9078921B2 (da) |
EP (2) | EP1880715A1 (da) |
JP (1) | JP5244102B2 (da) |
KR (1) | KR101424588B1 (da) |
CN (2) | CN103055316B (da) |
AU (1) | AU2007275177B2 (da) |
BR (1) | BRPI0715582A2 (da) |
CA (1) | CA2658395C (da) |
CY (1) | CY1118873T1 (da) |
DK (1) | DK2046298T3 (da) |
ES (1) | ES2612865T3 (da) |
HR (1) | HRP20170325T1 (da) |
HU (1) | HUE032551T2 (da) |
LT (1) | LT2046298T (da) |
MX (1) | MX2009000048A (da) |
PL (1) | PL2046298T3 (da) |
PT (1) | PT2046298T (da) |
RS (1) | RS55705B1 (da) |
RU (1) | RU2469708C2 (da) |
SI (1) | SI2046298T1 (da) |
WO (1) | WO2008009689A1 (da) |
ZA (1) | ZA200901110B (da) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5222550B2 (ja) * | 2007-12-27 | 2013-06-26 | 財團法人工業技術研究院 | 徐放性組成物およびその製造方法 |
US9161943B2 (en) | 2007-12-31 | 2015-10-20 | Industrial Technology Research Institute | Sustained release composition and manufacturing method thereof |
US8728516B2 (en) | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
EP2435052B1 (en) * | 2009-05-27 | 2015-07-15 | Hetero Research Foundation | Solid oral dosage forms of lamivudine with isomalt |
TWI471321B (zh) * | 2009-06-08 | 2015-02-01 | Abbott Gmbh & Co Kg | Bcl-2族群抑制劑之口服醫藥劑型 |
US20110034489A1 (en) * | 2009-07-31 | 2011-02-10 | Ranbaxy Laboratories Limited | Solid dosage forms of hiv protease inhibitors |
WO2011079127A1 (en) | 2009-12-22 | 2011-06-30 | Abbott Laboratories | Abt-263 capsule |
ES2613608T3 (es) * | 2010-03-10 | 2017-05-24 | Abbvie Ireland Unlimited Company | Composiciones sólidas |
KR102095698B1 (ko) | 2010-10-29 | 2020-04-01 | 애브비 인코포레이티드 | 아폽토시스―유도제를 포함하는 고체 분산체 |
UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
ES2603129T3 (es) | 2010-11-23 | 2017-02-23 | Abbvie Ireland Unlimited Company | Métodos de tratamiento utilizando inhibidores selectivos de Bcl-2 |
DK2643322T3 (da) | 2010-11-23 | 2017-12-11 | Abbvie Inc | Salte og krystalformer af et apoptosis-inducerende middel |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
PT2782584T (pt) | 2011-11-23 | 2021-09-02 | Therapeuticsmd Inc | Preparações e terapias de substituição para hormonoterapias naturais combinadas |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20130172375A1 (en) * | 2011-12-13 | 2013-07-04 | Hoffmann-La Roche Inc. | Pharmaceutical composition |
US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
EP2911651B1 (en) * | 2012-09-27 | 2016-06-22 | Basf Se | A storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin e-derivative and at least one hydrophilic polymer |
US9744240B2 (en) | 2012-09-27 | 2017-08-29 | Basf Se | Storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin E-derivative and at least one hydrophilic polymer |
US9789063B2 (en) | 2012-09-27 | 2017-10-17 | Basf Se | Storage-stable dust-free homogeneous particulate formulation |
JP6275726B2 (ja) * | 2012-09-27 | 2018-02-07 | ビーエーエスエフ ソシエタス・ヨーロピアBasf Se | 少なくとも1種の水溶性ビタミンe誘導体および少なくとも1種の親水性ポリマーを含む、保存において安定な無塵の均質な粒子製剤 |
KR102191562B1 (ko) * | 2012-11-07 | 2020-12-15 | 에스케이바이오팜 주식회사 | 난용성 약물의 고체분산체 및 이의 제조방법 |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
JP2017516768A (ja) | 2014-05-22 | 2017-06-22 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | 天然の併用ホルモン補充療法剤及び療法 |
RU2720680C2 (ru) | 2014-06-18 | 2020-05-12 | Ф. Хоффманн-Ля Рош Аг | Новая фармацевтическая композиция, содержащая неионные сурфактанты |
CN104523615B (zh) * | 2014-12-12 | 2017-07-04 | 常州康普药业有限公司 | 一种舒必利片及其制备方法 |
CN104784179A (zh) * | 2015-04-01 | 2015-07-22 | 重庆理工大学 | 替拉那韦在抗乳腺癌药物中的应用及抗乳腺癌药物 |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
KR20180126582A (ko) | 2016-04-01 | 2018-11-27 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 스테로이드 호르몬 약제학적 조성물 |
RU2619840C1 (ru) * | 2016-09-21 | 2017-05-18 | Общество с ограниченной ответственностью "Изварино Фарма" | Фармацевтическая композиция для лечения ВИЧ-инфекции |
RU2659693C1 (ru) * | 2017-06-30 | 2018-07-03 | Общество с ограниченной ответственностью "Изварино Фарма" | Фармацевтическая композиция, обладающая активностью против ВИЧ-инфекции |
CA3105187A1 (en) | 2018-06-28 | 2020-01-02 | Arx, Llc | Dispensing method for producing dissolvable unit dose film constructs |
KR102114550B1 (ko) * | 2018-07-10 | 2020-05-22 | 삼육대학교산학협력단 | 생리학적 체내 동태 연구 모델링을 이용한 약제학적 조성물의 제조 방법 |
CN111821309B (zh) * | 2020-04-30 | 2021-08-24 | 深圳市新阳唯康科技有限公司 | 一种具有改良溶出速度的达芦那韦组合物 |
CN117500923A (zh) | 2021-04-07 | 2024-02-02 | 巴特尔纪念研究院 | 用于鉴定和使用非病毒载体的快速设计、构建、测试和学习技术 |
CN117338733B (zh) * | 2023-10-12 | 2024-05-28 | 杭州和泽坤元药业有限公司 | 一种富马酸替诺福韦二吡呋酯片及其制备工艺 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY126358A (en) * | 1996-03-22 | 2006-09-29 | Glaxo Group Ltd | Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs |
DE19913692A1 (de) | 1999-03-25 | 2000-09-28 | Basf Ag | Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen |
US6375963B1 (en) * | 1999-06-16 | 2002-04-23 | Michael A. Repka | Bioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof |
DE19929361A1 (de) | 1999-06-25 | 2001-01-04 | Basf Ag | Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen |
GB0008785D0 (en) * | 2000-04-10 | 2000-05-31 | Novartis Ag | Organic compounds |
DE10026698A1 (de) | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
DE10046541A1 (de) * | 2000-09-19 | 2002-03-28 | Knoll Ag | Mechanisch stabile darreichungsformen, enthaltend Ubichinone |
US20050048112A1 (en) * | 2003-08-28 | 2005-03-03 | Jorg Breitenbach | Solid pharmaceutical dosage form |
EP1706606A1 (en) * | 2003-10-08 | 2006-10-04 | ECS Holdings, Inc. | System containing oxygen enriched diesel particulate filter and method thereof |
US20050096365A1 (en) * | 2003-11-03 | 2005-05-05 | David Fikstad | Pharmaceutical compositions with synchronized solubilizer release |
FR2861992B1 (fr) * | 2003-11-10 | 2007-07-20 | Sanofi Synthelabo | Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3-carboxamide. |
JP2007515458A (ja) * | 2003-12-23 | 2007-06-14 | テイボテク・フアーマシユーチカルズ・リミテツド | Hivプロテアーゼ阻害剤の自己ミクロ乳化性薬剤送達システム |
FR2866192B1 (fr) * | 2004-02-11 | 2006-04-28 | Johnson Controls Tech Co | Systeme et procede automatiques de reparation d'une carte electronique |
US7790190B2 (en) | 2004-03-20 | 2010-09-07 | Yasoo Health, Inc. | Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid |
US7318503B2 (en) | 2004-04-26 | 2008-01-15 | Akebono Corporation (North America) | Pad retaining clips |
JP4629104B2 (ja) * | 2004-05-21 | 2011-02-09 | 日本たばこ産業株式会社 | 4−オキソキノリン誘導体および抗hiv剤を含む併用剤 |
WO2006060817A1 (en) * | 2004-12-03 | 2006-06-08 | Abbott Laboratories | Pharmaceutical compositions |
-
2006
- 2006-07-19 EP EP06015076A patent/EP1880715A1/en not_active Withdrawn
-
2007
- 2007-07-17 CA CA2658395A patent/CA2658395C/en not_active Expired - Fee Related
- 2007-07-17 PT PT77876589T patent/PT2046298T/pt unknown
- 2007-07-17 WO PCT/EP2007/057392 patent/WO2008009689A1/en active Application Filing
- 2007-07-17 HU HUE07787658A patent/HUE032551T2/en unknown
- 2007-07-17 EP EP07787658.9A patent/EP2046298B1/en active Active
- 2007-07-17 KR KR1020087032146A patent/KR101424588B1/ko active IP Right Grant
- 2007-07-17 LT LTEP07787658.9T patent/LT2046298T/lt unknown
- 2007-07-17 ES ES07787658.9T patent/ES2612865T3/es active Active
- 2007-07-17 US US12/305,870 patent/US9078921B2/en not_active Expired - Fee Related
- 2007-07-17 JP JP2009519974A patent/JP5244102B2/ja active Active
- 2007-07-17 RU RU2009105479/15A patent/RU2469708C2/ru active
- 2007-07-17 CN CN201210270063.XA patent/CN103055316B/zh active Active
- 2007-07-17 MX MX2009000048A patent/MX2009000048A/es active IP Right Grant
- 2007-07-17 RS RS20170203A patent/RS55705B1/sr unknown
- 2007-07-17 BR BRPI0715582-4A patent/BRPI0715582A2/pt not_active IP Right Cessation
- 2007-07-17 AU AU2007275177A patent/AU2007275177B2/en not_active Ceased
- 2007-07-17 DK DK07787658.9T patent/DK2046298T3/da active
- 2007-07-17 SI SI200731895A patent/SI2046298T1/sl unknown
- 2007-07-17 CN CN2007800268668A patent/CN101489537B/zh active Active
- 2007-07-17 PL PL07787658T patent/PL2046298T3/pl unknown
-
2009
- 2009-02-17 ZA ZA2009/01110A patent/ZA200901110B/en unknown
-
2015
- 2015-07-14 US US14/799,430 patent/US9616130B2/en not_active Expired - Fee Related
-
2017
- 2017-02-17 CY CY20171100221T patent/CY1118873T1/el unknown
- 2017-02-28 HR HRP20170325TT patent/HRP20170325T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9616130B2 (en) | Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same | |
US10463739B2 (en) | Solid retard formulations based on solid dispersions | |
EP2303242B1 (en) | Pharmaceutical dosage form comprising polymeric carrier composition | |
EP1898954B1 (en) | Composition and dosage form comprising a solid or semi-solid matrix | |
EP1912626B1 (en) | Dosage forms with improved bioavailability | |
ES2350001T3 (es) | Composición y forma de dosificación que comprende una matriz sólida o semi-sólida. |